Subscribe to our newsletter for a refreshing cocktail (or mocktail) of LGBTQ+ entertainment and pop culture, served up with a side of eye-candy.The new form of the drug is called “cabotegravir ultra long-acting” (CAB-ULA).ViiV presented its findings last week at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) in Denver, Colorado.The trial included 70 participants. Researchers tested injecting the new formulation of the drug.